Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2. - Test2 - elhamkhani - TriplyDB

Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.

Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.

http://www.wikidata.org/entity/Q33570529

about

The osteocyte as a therapeutic target in the treatment of osteoporosis LRP5 and LRP6 in development and disease Control of bone formation by the serpentine receptor Frizzled-9 Dkk1 stabilizes Wnt co-receptor LRP6: implication for Wnt ligand-induced LRP6 down-regulation.Identification of novel genes associated with fracture healing in osteoporosis induced by Krm2 overexpression or Lrp5 deficiency.Osteoblast-specific Krm2 overexpression and Lrp5 deficiency have different effects on fracture healing in mice.The transcriptional profile of mesenchymal stem cell populations in primary osteoporosis is distinct and shows overexpression of osteogenic inhibitors High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes.Ablation of the pro-apoptotic protein Bax protects mice from glucocorticoid-induced bone growth impairment Update on Wnt signaling in bone cell biology and bone disease.Serum levels of sclerostin, Dickkopf-1, and secreted frizzled-related protein-4 are not changed in individuals with high bone mass causing mutations in LRP5.Wnt signaling in bone development and disease: making stronger bone with Wnts The role of midkine in skeletal remodelling.Wnt and the Wnt signaling pathway in bone development and disease.Effects of pulsed electromagnetic fields on postmenopausal osteoporosis.Structure of the Dual-Mode Wnt Regulator Kremen1 and Insight into Ternary Complex Formation with LRP6 and Dickkopf.The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5.Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin.Predominant role of PDGF receptor transactivation in Wnt3a-induced osteoblastic cell proliferation.Bioinformatics analysis of gene expression profile in callus tissues of osteoporotic phenotype mice induced by osteoblast-specific Krm2 overexpression.

P2860

Q27009129-93BA828B-B966-4590-8D3D-5F72BE8F9EDB Q27692072-F43A4EC9-06E7-4150-93F3-5B7F4C992B7E Q28587080-DD924F58-FDF0-4B4B-8E6D-B076151C5EF8 Q33603037-5E740CA6-3642-4847-A920-F0EFEA8B1AAF Q33702201-D25B4717-2B49-4223-9FDC-D43F77210EE8 Q33952489-EF2E4EDC-02A6-474A-8ED4-0E6865D8CF68 Q34428195-8D46EE84-6A23-4009-BBEC-49CE6D4DA07A Q35755147-F16498C1-DF8B-49B3-973F-AAEEE058E9E6 Q35839866-0A5791AA-6B04-4A02-B01A-7438DD4494AD Q36083303-695F5B30-21BA-4673-BCF0-65FC52C86AFC Q36318608-0A3EC2C7-A10E-4C97-A167-437B55F4FFB5 Q36418026-1D059CF3-D589-4EAF-9A40-B1943F52439C Q37585395-80372AA9-4213-40C9-BA14-DBF96D77B139 Q37724188-BC145DAC-8F70-4CD0-8D00-05DA35622393 Q38664528-F686DEE5-7ED8-41CB-AB56-7775380BED8B Q41033242-2BE24655-6BFF-480C-BD29-C5E52F501F59 Q41498366-C7F2D747-E917-4AC0-9839-3714DA6B1903 Q42174982-8C55FEFC-1624-4F1C-B6D1-28960D85F7FB Q47215693-689E724B-1F1F-4D0C-8512-41B596F52903 Q47881918-951EA234-9BD5-4258-8ADA-6D4AB93BB2F3

P2860

Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.

http://www.wikidata.org/entity/Q33570529

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.

@ast

Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.

@en

Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.

@nl

type

label

Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.

@ast

Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.

@en

Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.

@nl

prefLabel

Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.

@ast

Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.

@en

Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2.

@nl

P1433

Q33570529-B70E387C-F095-4AE4-B852-34B490C16338

P1476

Q33570529-012FC95F-92E6-49A1-B2BE-2B0D312CDB05

P2093

Q33570529-212F8B15-E624-4CF5-A550-F6FBB8302681

Q33570529-3329DF4A-1FC5-4384-835F-0EAAFFD496FB

Q33570529-3CD10E6E-3800-4F3C-AF98-42ADB37BAF30

Q33570529-6A682997-F061-4E3E-A1BD-02FA967F38B1

Q33570529-6EDCD604-08F9-4B43-A03D-6F52B8E70AE5

Q33570529-81EED036-A83D-4DCB-B802-A1B63D4868B9

Q33570529-85BA0731-B9D6-4192-B92D-FB8282EC646D

Q33570529-89D11C1D-8B1E-4297-B40A-28392DB346D5

Q33570529-952D2272-5854-4B9B-953E-3A7EB110B21A

Q33570529-9F01015C-FCD3-4AE7-8B0E-54B2C74AC25C

P2860

Q33570529-07C4EF9D-4547-4DD0-83AD-E1AA93FC9D6C

Q33570529-220AF7A6-5855-4D84-8F3E-1E26241F2313

Q33570529-2A25EE9B-83A8-4265-BB55-44C405B87E0E

Q33570529-2A94BFFD-2935-4AF8-96D3-60E7F863939E

Q33570529-2B7F6958-543D-4490-B08A-06555C3FA453

Q33570529-2BEAD701-8C23-473F-9505-B179484E9CCB

Q33570529-36B26200-FE2C-4A1E-AE11-24537FB4E362

Q33570529-373F0AB3-D35C-407D-AE36-D219E1D4D23F

Q33570529-420CE5E2-47B8-448B-9B12-EEC3F7D3B03B

Q33570529-42994DC4-A9C7-4534-8C53-D313061EE725

P304

Q33570529-88EF91C5-C1C3-43CB-B17D-EDD604511CC4

P31

Q33570529-EEA23B6D-0C26-4747-8ED2-6551AC8562EC

P356

Q33570529-3AFA2EB3-F421-48FA-A8F4-845C6CA4F9C2

P407

Q33570529-49B6EE3F-1FCC-4F2D-BF82-E26ED64DA573

P433

Q33570529-89795AC7-1C2B-4269-80B1-AB4A729D241A

P478

Q33570529-EFDFB0D1-EFE2-4796-93F8-DB9DEE9B4550

P50

Q33570529-9C9C4BE7-C932-409F-A30F-C3EFF14BB431

P577

Q33570529-DF489088-37F6-45E3-8B31-33935FF2FFF7

P5875

Q33570529-C127D3EC-45AD-4FEE-AA16-15EAC4B6B6C6

P698

Q33570529-68C97FBA-4CAA-4435-AD2F-9CB04061BF7A

P921

Q33570529-8A45B04F-33F1-43CE-B5F1-0B37744F5365

P932

Q33570529-D504ED7C-8535-4C2B-8490-62C2A67A0597

P356

JOURNAL.PONE.0010309

P1433

P1476

Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2

@en

P2093

Alexander S Spiro

http://www.w3.org/2001/XMLSchema#string

Anke Baranowsky

http://www.w3.org/2001/XMLSchema#string

Arndt F Schilling

http://www.w3.org/2001/XMLSchema#string

Christof Niehrs

http://www.w3.org/2001/XMLSchema#string

Felix W Friedrich

http://www.w3.org/2001/XMLSchema#string

Hiroaki Saito

http://www.w3.org/2001/XMLSchema#string

Joachim Albers

http://www.w3.org/2001/XMLSchema#string

Jochen Schulze

http://www.w3.org/2001/XMLSchema#string

Jozef Zustin

http://www.w3.org/2001/XMLSchema#string

Kristina Ellwanger

http://www.w3.org/2001/XMLSchema#string

P2860

R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6

Osteocyte control of bone formation via sclerostin, a novel BMP antagonist

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor

A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium

PCOLCE2 encodes a functional procollagen C-proteinase enhancer (PCPE2) that is a collagen-binding protein differing in distribution of expression and post-translational modification from the previously described PCPE1

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait

Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

Osteogenesis imperfecta: prospects for molecular therapeutics

P304

e10309

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0010309

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-04-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43535851

http://www.w3.org/2001/XMLSchema#string

P698

20436912

http://www.w3.org/2001/XMLSchema#string

P921

transmembrane protein

P932

2860505

http://www.w3.org/2001/XMLSchema#string